|
1
|
Nault JC, Sutter O, Nahon P, Ganne-Carrié
N and Séror O: Percutaneous treatment of hepatocellular carcinoma:
State of the art and innovations. J Hepatol. 68:783–797.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Menke K, Schwermer M, Falke K, Felenda J,
Beckmann C, Stintzing F, Voigt A, Schramm A and Zuzak TJ: Taraxacum
officinale extract induces antitumorigenic effects in ovarian
carcinoma cell lines. Eur J Gynaecol Oncol. 40:106–112. 2019.
|
|
3
|
Labeur TA, Achterbergh R, Takkenberg B,
Van Delden O, Mathôt R and Klümpen HJ: Sorafenib for patients with
hepatocellular carcinoma and Child-Pugh B liver cirrhosis: Lessons
learned from a terminated study. Oncologist. 24:1–6.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ray EM and Sanoff HK: Optimal therapy for
patients with hepatocellular carcinoma and resistance or
intolerance to sorafenib: Challenges and solutions. J Hepatocell
Carcinoma. 4:131–138. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hickson GR and O'Farrell PH: Anillin: A
pivotal organizer of the cytokinetic machinery. Biochem Soc Trans.
36:439–441. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Piekny AJ and Maddox AS: The myriad roles
of Anillin during cytokinesis. Semin Cell Dev Biol. 21:881–891.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
D'Avino PP, Archambault V, Przewloka MR,
Zhang W, Laue ED and Glover DM: Isolation of protein complexes
involved in mitosis and cytokinesis from Drosophila cultured
cells. Methods Mol Biol. 545:99–112. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Oegema K, Savoian MS, Mitchison TJ and
Field CM: Functional analysis of a human homologue of the
Drosophila actin binding protein anillin suggests a role in
cytokinesis. J Cell Biol. 150:539–552. 2000.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hickson GR and O'Farrell PH: Rho-dependent
control of anillin behavior during cytokinesis. J Cell Biol.
180:285–294. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hall PA, Todd CB, Hyland PL, McDade SS,
Grabsch H, Dattani M, Hillan KJ and Russell SE: The septin-binding
protein anillin is overexpressed in diverse human tumors. Clin
Cancer Res. 11:6780–6786. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Olakowski M, Tyszkiewicz T, Jarzab M, Król
R, Oczko-Wojciechowska M, Kowalska M, Kowal M, Gala GM, Kajor M,
Lange D, et al: NBL1 and anillin (ANLN) genes over-expression in
pancreatic carcinoma. Folia Histochem Cytobiol. 47:249–255.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shimizu S, Seki N, Sugimoto T, Horiguchi
S, Tanzawa H, Hanazawa T and Okamoto Y: Identification of molecular
targets in head and neck squamous cell carcinomas based on
genome-wide gene expression profiling. Oncol Rep. 18:1489–1497.
2007.PubMed/NCBI
|
|
13
|
Suzuki C, Daigo Y, Ishikawa N, Kato T,
Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical
role in human lung carcinogenesis through the activation of RHOA
and by involvement in the phosphoinositide 3-kinase/AKT pathway.
Cancer Res. 65:11314–11325. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhou W, Wang Z, Shen N, Pi W, Jiang W,
Huang J, Hu Y, Li X and Sun L: Knockdown of ANLN by lentivirus
inhibits cell growth and migration in human breast cancer. Mol Cell
Biochem. 398:11–19. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Skrzypski M, Jassem E, Taron M, Sanchez
JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, et
al: Three-gene expression signature predicts survival in
early-stage squamous cell carcinoma of the lung. Clin Cancer Res.
14:4794–4799. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lian YF, Huang YL, Wang JL, Deng MH, Xia
TL, Zeng MS, Chen MS, Wang HB and Huang YH: Anillin is required for
tumor growth and regulated by miR-15a/miR-16-1 in HBV-related
hepatocellular carcinoma. Aging (Albany NY). 10:1884–1901.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li L, Huang K, Zhao H, Chen B, Ye Q and
Yue J: CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell
division in cell cycle may be a critical process in hepatocellular
carcinoma. Cell Cycle. 19:1236–1252. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) μethod. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Abdelnabi M, Almaghraby A, Saleh Y and Abd
Elsamad S: Hepatocellular carcinoma with a direct right atrial
extension in an HCV patient previously treated with direct-acting
antiviral therapy: A case report. Egypt Heart J.
71(5)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Salem R, Gabr A, Riaz A, Mora R, Ali R,
Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, et al:
Institutional decision to adopt Y90 as primary treatment for
hepatocellular carcinoma informed by a 1,000-patient 15-year
experience. Hepatology. 68:1429–1440. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lünse S, Heidecke CD and Partecke LI:
Current topics and perspectives in surgical management of
hepatocellular carcinoma. In: Hepatocellular Carcinoma.
Tirnitz-Parker JE (eds). Codon Publications, Brisbane, AU,
pp111-126, 2019.
|
|
22
|
Colombo M: Treatment of hepatocellular
carcinoma. Antiviral Res. 52:209–215. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang Y, Zhao Z, Xie C and Zhao Y:
Dual-targeting liposome modified by glutamic hexapeptide and folic
acid for bone metastatic breast cancer. Chem Phys Lipids.
228(104882)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhao Z, Zhao Y, Xie C, Chen C, Lin D, Wang
S, Lin D, Cui X, Guo Z and Zhou J: Dual-active targeting liposomes
drug delivery system for bone metastatic breast cancer: Synthesis
and biological evaluation. Chem Phys Lipids.
223(104785)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Obiorah IE, Chahine J, Park BU, Ko K,
deGuzman J and Kallakury B: Well differentiated arginase-1 negative
hepatocellular carcinoma. Transl Gastroenterol Hepatol.
4(66)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang G, Shen W, Cui L, Chen W, Hu X and Fu
J: Overexpression of Anillin (ANLN) is correlated with colorectal
cancer progression and poor prognosis. Cancer Biomark. 16:459–465.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Magnusson K, Gremel G, Rydén L, Pontén V,
Uhlén M, Dimberg A, Jirström K and Pontén F: ANLN is a prognostic
biomarker independent of Ki-67 and essential for cell cycle
progression in primary breast cancer. BMC Cancer.
16(904)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Long X, Zhou W, Wang Y and Liu S:
Prognostic significance of ANLN in lung adenocarcinoma. Oncol Lett.
16:1835–1840. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zeng S, Yu X, Ma C, Song R, Zhang Z, Zi X,
Chen X, Wang Y, Yu Y, Zhao J, et al: Transcriptome sequencing
identifies ANLN as a promising prognostic biomarker in bladder
urothelial carcinoma. Sci Rep. 7(3151)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang Z, Chen J, Zhong MZ, Huang J, Hu YP,
Feng DY, Zhou ZJ, Luo X, Liu ZQ, Jiang WZ, et al: Overexpression of
ANLN contributed to poor prognosis of anthracycline-based
chemotherapy in breast cancer patients. Cancer Chemother Pharmacol.
79:535–543. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Weinberger P, Ponny SR, Xu H, Bai S,
Smallridge R, Copland J and Sharma A: Cell cycle M-phase genes are
highly upregulated in anaplastic thyroid carcinoma. Thyroid.
27:236–252. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pandi NS, Manimuthu M, Harunipriya P,
Murugesan M, Asha GV and Rajendran S: In silico analysis of
expression pattern of a Wnt/β-catenin responsive gene ANLN in
gastric cancer. Gene. 545:23–29. 2014.PubMed/NCBI View Article : Google Scholar
|
